Chrissy Buteas, President and CEO of the HealthCare Institute of New Jersey, issued a statement regarding the recent appointments to the Prescription Drug Affordability Council (PDAC) by the State.
Buteas highlighted the complexity involved in drug development and noted that intermediaries such as insurers and pharmacy benefit managers (PBMs) account for more than half of a medication's final price. She emphasized that PDAC appointees should have unbiased expertise across the prescription drug supply chain and avoid actions that could deter investment in medical innovation.
She warned against actions that might undermine investments made by the State, academic medical centers, and local economic development agencies aimed at fostering growth in New Jersey's life sciences sector. "We hope that the Council’s actions will not jeopardize our ability to do what we do best – saving lives around the world by finding new treatments and cures in New Jersey," she stated.
